Cathepsin D as a potential prognostic marker for lung adenocarcinoma

Pathology Research and Practice

Volumn 208, Issue 9, 2012, Pages 534-540

  Mimae, Takahiro ^a,b,c   Tsuta, Koji ^a   Maeshima, Akiko M ^a   Okada, Morihito ^c   Asamura, Hisao ^a   Kondo, Tadashi ^b   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cathepsin D; Differentiation; Lung adenocarcinoma; Predictive factor; Tumor marker

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ALK GENE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CLINICAL FEATURE; EGFR GENE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN D; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865280129     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.05.020     Document Type: Article

References (48)

1. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
2. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., Goldstraw P. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2007, 2:694-705.
3. Devesa S.S., Bray F., Vizcaino A.P., Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer 2005, 117:294-299.
4. Little A.G., DeMeester T.R., Ferguson M.K., Skinner D.B., Hoffman P.C., Skosey C., Blough R.R., Golomb H.M. Modified stage I (T1N0M0 T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy. Surgery 1986, 100:621-628.
5. Hosako M., Muto T., Nakamura Y., Tsuta K., Tochigi N., Tsuda H., Asamura H., Tomonaga T., Kawai A., Kondo T. Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker. J. Proteomics 2011, 75:833-844.
6. von Figura K., Hasilik A. Lysosomal enzymes and their receptors. Annu. Rev. Biochem. 1986, 55:167-193.
7. Hasilik A., Neufeld E.F. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J. Biol. Chem. 1980, 255:4946-4950.
8. Kornfeld S., Mellman I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 1989, 5:483-525.
9. Dittmer F., Pohlmann R., von Figura K. The phosphorylation pattern of oligosaccharides in secreted procathepsin D is glycosylation site-specific and independent of the expression of mannose 6-phosphate receptors. J. Biol. Chem. 1997, 272:852-858.
10. Garcia M., Derocq D., Pujol P., Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5:1809-1814.
11. Rochefort H., Capony F., Garcia M., Cavailles V., Freiss G., Chambon M., Morisset M., Vignon F. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?. J. Cell. Biochem. 1987, 35:17-29.
12. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S. Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possible importance of its expression in tumor cells and stromal cells, and its intracellular polarization in tumor cells. J. Surg. Oncol. 1997, 65:10-19.
13. Wang Z., Zhao X. Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes. Zhonghua Jie He He Hu Xi Za Zhi 1998, 21:164-166.
14. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics tumors of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours 2004, IARC Press, Lyon.
15. Tsuta K., Tanabe Y., Yoshida A., Takahashi F., Maeshima A.M., Asamura H., Tsuda H. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3 S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J. Thorac. Oncol. 2011, 6:1190-1199.
16. Society J.L.C. General Rule for Clinical and Pathologic Recording of Lung Cancer 1999, Kanahara, Tokyo. 5th ed.
17. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., Beer D.G., Powell C.A., Riely G.J., Van Schil P.E., Garg K., Austin J.H., Asamura H., Rusch V.W., Hirsch F.R., Scagliotti G., Mitsudomi T., Huber R.M., Ishikawa Y., Jett J., Sanchez-Cespedes M., Sculier J.P., Takahashi T., Tsuboi M., Vansteenkiste J., Wistuba I., Yang P.C., Aberle D., Brambilla C., Flieder D., Franklin W., Gazdar A., Gould M., Hasleton P., Henderson D., Johnson B., Johnson D., Kerr K., Kuriyama K., Lee J.S., Miller V.A., Petersen I., Roggli V., Rosell R., Saijo N., Thunnissen E., Tsao M., Yankelewitz D. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6:244-285.
18. Fukui T., Ohe Y., Tsuta K., Furuta K., Sakamoto H., Takano T., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Asamura H., Tsuchida T., Kaneko M., Kusumoto M., Yamamoto S., Yoshida T., Tamura T. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin. Cancer Res. 2008, 14:4751-4757.
19. Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., Sekine I., Grogan T.M., Fukayama M., Shibata T., Furuta K., Kohno T., Tsuda H. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J. Thorac. Oncol. 2011, 6:1677-1686.
20. Berchem G., Glondu M., Gleizes M., Brouillet J.P., Vignon F., Garcia M., Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002, 21:5951-5955.
21. Glondu M., Coopman P., Laurent-Matha V., Garcia M., Rochefort H., Liaudet-Coopman E. A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene 2001, 20:6920-6929.
22. Glondu M., Liaudet-Coopman E., Derocq D., Platet N., Rochefort H., Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002, 21:5127-5134.
23. Hu L., Roth J.M., Brooks P., Luty J., Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008, 68:4666-4673.
24. Khalkhali-Ellis Z., Abbott D.E., Bailey C.M., Goossens W., Margaryan N.V., Gluck S.L., Reuveni M., Hendrix M.J. IFN-gamma regulation of vacuolar pH, cathepsin D processing and autophagy in mammary epithelial cells. J. Cell. Biochem. 2008, 105:208-218.
25. Liaudet E., Garcia M., Rochefort H., Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 1994, 9:1145-1154.
26. Ohri S.S., Vashishta A., Proctor M., Fusek M., Vetvicka V. The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells. Int. J. Oncol. 2008, 32:491-498.
27. Aziz S., Pervez S., Khan S., Kayani N., Rahbar M. Immunohistochemical cathepsin-D expression in breast cancer: correlation with established pathological parameters and survival. Pathol. Res. Pract. 2001, 197:551-557.
28. Jahkola T., Toivonen T., von Smitten K., Virtanen I., Wasenius V.M., Blomqvist C. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br. J. Cancer 1999, 80:167-174.
29. Chung C.K., Zaino R., Stryker J.A., O'Neill M., DeMuth W.E. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann. Thorac. Surg. 1982, 33:599-604.
30. Gajra A., Newman N., Gamble G.P., Abraham N.Z., Kohman L.J., Graziano S.L. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 2003, 42:51-57.
31. Ichinose Y., Yano T., Asoh H., Yokoyama H., Yoshino I., Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J. Thorac. Cardiovasc. Surg. 1995, 110:601-605.
32. Nose N., Sugio K., Oyama T., Nozoe T., Uramoto H., Iwata T., Onitsuka T., Yasumoto K. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J. Clin. Oncol. 2009, 27:411-417.
33. Ou S.H., Ziogas A., Zell J.A. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J. Thorac. Oncol. 2010, 5:420-427.
34. Chou T.Y., Chiu C.H., Li L.H., Hsiao C.Y., Tzen C.Y., Chang K.T., Chen Y.M., Perng R.P., Tsai S.F., Tsai C.M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 2005, 11:3750-3757.
35. Haneda H., Sasaki H., Lindeman N., Kawano O., Endo K., Suzuki E., Shimizu S., Yukiue H., Kobayashi Y., Yano M., Fujii Y. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn. J. Clin. Oncol. 2006, 36:69-75.
36. M. Sonobe, M. Kobayashi, M. Ishikawa, R. Kikuchi, E. Nakayama, T. Takahashi, T. Menju, K. Takenaka, R. Miyahara, C.L. Huang, K. Okubo, T. Bando, H. Date, Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas, Ann. Surg. Oncol., in press.
37. Yoshida A., Tsuta K., Nakamura H., Kohno T., Takahashi F., Asamura H., Sekine I., Fukayama M., Shibata T., Furuta K., Tsuda H. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 2011, 35:1226-1234.
38. Paech D.C., Weston A.R., Pavlakis N., Gill A., Rajan N., Barraclough H., Fitzgerald B., Van Kooten M. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:55-63.
39. Sandler A. Bevacizumab in non small cell lung cancer. Clin. Cancer Res. 2007, 13:s4613-s4616.
40. Anagnostou V.K., Syrigos K.N., Bepler G., Homer R.J., Rimm D.L. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J. Clin. Oncol. 2009, 27:271-278.
41. Lin D.M., Zou S.M., Lu N., Wen P., Liu X.Y., He Z.G. TTF-1 expression and its diagnostic application in lung carcinomas. Zhonghua Zhong Liu Za Zhi 2004, 26:615-617.
42. Martins S.J., Takagaki T.Y., Silva A.G., Gallo C.P., Silva F.B., Capelozzi V.L. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 2009, 64:105-109.
43. Yatabe Y., Mitsudomi T., Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 2002, 26:767-773.
44. Ruibal A., Nunez M.I., Rio Mdel C., Garcia Diez S., Rodriguez J., Alvarez de Linera J.F. Cytosolic cathepsin D levels in squamous carcinomas of the lung. Med. Clin. (Barc.) 2003, 120:81-84.
45. Agnantis N.J., Goussia A.C., Batistatou A., Stefanou D. Tumor markers in cancer patients. An update of their prognostic significance. Part II. In Vivo 2004, 18:481-488.
46. Reid W.A., Valler M.J., Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J. Clin. Pathol. 1986, 39:1323-1330.
47. Guicciardi M.E., Leist M., Gores G.J. Lysosomes in cell death. Oncogene 2004, 23:2881-2890.
48. Agostinelli E., Seiler N. Lysosomotropic compounds and spermine enzymatic oxidation products in cancer therapy (review). Int. J. Oncol. 2007, 31:473-484.